The Democratic Republic of the Congo and Angola (DRCAA) stands on the world stage of the year 2060 – forged in the crucible of the synthetic nano-parasite (SNP/NanoSinp) and BioSev/Vaccine Genocide dual crisis, yet governed by a ruthless corporatocracy. Power resides not in elected officials, but in the boardrooms of the corporations that form its ruling oligarchy.

The nation's heart and capital is Kinshasa-Brazzaville, a purpose-built megacity sprawling across Ile M'Bamou in the middle of the Congo River, housing the vast majority of the DRCAA's estimated 30 million inhabitants. Across the Congo lie the skeletal remnants of Old Kinshasa and Old Brazzaville, vast urban graveyards emptied by the dual crisis, reduced to decaying suburbs.

Within Kinshasa-Brazzaville itself, the corporate oligarchy rules. While Congo Saviour Capital (CSC) under its CEO Jenny wields significant influence, entities like CPU manufacturer ACF Huang-Opaia and other conglomerates share power. Their collective interests dictate DRCAA policy, security, and the flow of life. The exploitation of the bioinsecure workforce and the strategic distribution of NeoGuard™ are fundamental tools used by all these ruling corporations to maintain productivity and control.

NeoGuard™ access remains the critical societal divider, managed by the corporatocracy to sustain essential labour and protect their executive elite. Society is rigidly stratified, with a vast bioinsecure population facing precarious health and survival odds, dependent on the limited and controlled supply of the very SNP-treatment that mitigates, but does not cure, the effects of the ongoing biological crisis.

Beyond the capital and key industrial zones like Cabinda, the DRCAA's vast territories are divided into corporate spheres of influence, where resources are extracted and order is enforced according to the dictates of the ruling firms. The DRCAA is a nation in name, but a corporate battleground in practice, a significant hyper-capitalist power center defined by exploitation and the harsh realities of managed biosecurity.